IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).

Authors

Rebecca Dent

National Cancer Center, Singapore, Singapore

Rebecca Dent , Fabrice Andre , Anthony Goncalves , Sherko Kummel , Miguel Martin , Peter Schmid , Florian Schuetz , Sandra M. Swain , Valerie Easton , Erika Pollex , Javier Cortés

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).

First Author: Shom Goel

insert_chart_outlined

Poster

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

bookmark_border

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC).

First Author: Javier Cortés

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).

First Author: Leisha A. Emens

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE.

First Author: Thomas Powles